SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance
Therapeutic responses to identical chemotherapy regimens often vary significantly among patients with the same type of cancer, underscoring the need for additional biomarkers to identify individuals most likely to benefit from specific treatments. The expression of SLFN11 (Schlafen11) has been ident...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1582738/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850060478784471040 |
|---|---|
| author | Kunzhong Zhou Yuewen Li Weifang Wang Yilin Chen Bingyan Qian Yiteng Liang Hongmei Li Ruiting Xu Li Zhuang |
| author_facet | Kunzhong Zhou Yuewen Li Weifang Wang Yilin Chen Bingyan Qian Yiteng Liang Hongmei Li Ruiting Xu Li Zhuang |
| author_sort | Kunzhong Zhou |
| collection | DOAJ |
| description | Therapeutic responses to identical chemotherapy regimens often vary significantly among patients with the same type of cancer, underscoring the need for additional biomarkers to identify individuals most likely to benefit from specific treatments. The expression of SLFN11 (Schlafen11) has been identified as a potential biomarker for predicting patient responses to DNA-damaging agents and PARP inhibitors, as it irreversibly blocks DNA replication under replication stress, thereby increasing the sensitivity of cancer cells to various DNA-damaging agents and PARP inhibitors. Preclinical and clinical trial data suggest that SLFN11 can predict therapeutic responses to multiple DNA- targeted drugs, including platinum-based agents, topoisomerase I/II inhibitors, DNA synthesis inhibitors, and PARP inhibitors. Leveraging the expression status of SLFN11 or modulating its expression offers exciting possibilities for clinical applications. In this review, we summarize the structure and function of SLFN11, as well as its progress as a biomarker across various cancer types. We also review the regulation of SLFN11 expression, its dynamic expression patterns, and potential strategies for combination therapies to enhance efficacy based on SLFN11 status. Furthermore, we discuss the potential of SLFN11 expression status in overcoming resistance to DNA-damaging drugs, optimizing treatment strategies, and advancing precision cancer therapy. |
| format | Article |
| id | doaj-art-6d13e84bb74c4ac89596756a3003ef62 |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-6d13e84bb74c4ac89596756a3003ef622025-08-20T02:50:32ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-07-011510.3389/fonc.2025.15827381582738SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidanceKunzhong ZhouYuewen LiWeifang WangYilin ChenBingyan QianYiteng LiangHongmei LiRuiting XuLi ZhuangTherapeutic responses to identical chemotherapy regimens often vary significantly among patients with the same type of cancer, underscoring the need for additional biomarkers to identify individuals most likely to benefit from specific treatments. The expression of SLFN11 (Schlafen11) has been identified as a potential biomarker for predicting patient responses to DNA-damaging agents and PARP inhibitors, as it irreversibly blocks DNA replication under replication stress, thereby increasing the sensitivity of cancer cells to various DNA-damaging agents and PARP inhibitors. Preclinical and clinical trial data suggest that SLFN11 can predict therapeutic responses to multiple DNA- targeted drugs, including platinum-based agents, topoisomerase I/II inhibitors, DNA synthesis inhibitors, and PARP inhibitors. Leveraging the expression status of SLFN11 or modulating its expression offers exciting possibilities for clinical applications. In this review, we summarize the structure and function of SLFN11, as well as its progress as a biomarker across various cancer types. We also review the regulation of SLFN11 expression, its dynamic expression patterns, and potential strategies for combination therapies to enhance efficacy based on SLFN11 status. Furthermore, we discuss the potential of SLFN11 expression status in overcoming resistance to DNA-damaging drugs, optimizing treatment strategies, and advancing precision cancer therapy.https://www.frontiersin.org/articles/10.3389/fonc.2025.1582738/fullSchlafen11 (SLFN11)DNA damaging agentsPARP inhibitorspan-cancerDNA damage repair mechanismsepigenetics |
| spellingShingle | Kunzhong Zhou Yuewen Li Weifang Wang Yilin Chen Bingyan Qian Yiteng Liang Hongmei Li Ruiting Xu Li Zhuang SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance Frontiers in Oncology Schlafen11 (SLFN11) DNA damaging agents PARP inhibitors pan-cancer DNA damage repair mechanisms epigenetics |
| title | SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance |
| title_full | SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance |
| title_fullStr | SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance |
| title_full_unstemmed | SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance |
| title_short | SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance |
| title_sort | slfn11 a pan cancer biomarker for dna targeted drugs sensitivity and therapeutic strategy guidance |
| topic | Schlafen11 (SLFN11) DNA damaging agents PARP inhibitors pan-cancer DNA damage repair mechanisms epigenetics |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1582738/full |
| work_keys_str_mv | AT kunzhongzhou slfn11apancancerbiomarkerfordnatargeteddrugssensitivityandtherapeuticstrategyguidance AT yuewenli slfn11apancancerbiomarkerfordnatargeteddrugssensitivityandtherapeuticstrategyguidance AT weifangwang slfn11apancancerbiomarkerfordnatargeteddrugssensitivityandtherapeuticstrategyguidance AT yilinchen slfn11apancancerbiomarkerfordnatargeteddrugssensitivityandtherapeuticstrategyguidance AT bingyanqian slfn11apancancerbiomarkerfordnatargeteddrugssensitivityandtherapeuticstrategyguidance AT yitengliang slfn11apancancerbiomarkerfordnatargeteddrugssensitivityandtherapeuticstrategyguidance AT hongmeili slfn11apancancerbiomarkerfordnatargeteddrugssensitivityandtherapeuticstrategyguidance AT ruitingxu slfn11apancancerbiomarkerfordnatargeteddrugssensitivityandtherapeuticstrategyguidance AT lizhuang slfn11apancancerbiomarkerfordnatargeteddrugssensitivityandtherapeuticstrategyguidance |